EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Zynteglo

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
PSUSA/10769 /202105	Periodic Safety Update EU Single assessment - betibeglogene autotemcel	13/01/2022	n/a		PRAC Recommendation - maintenance
IB/0029	B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method	10/12/2021	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

N/0030	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	09/12/2021	22/03/2022	PL	
IB/0028	B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method	29/09/2021	n/a		
II/0025	B.I.e.2 - Introduction of a post approval change management protocol related to the AS	16/09/2021	n/a		
A20/0023	Pursuant to Article 20 of Regulation (EC) No 726/2004 the European Commission requested on 18 February 2021 the opinion of the European Medicines Agency further to concerns regarding a possible causal association between the lentiviral vector or other aspects related to the therapy and the onset of AML/MDS in patients receiving a medicinal product for treatment of sickle cell disease containing the same lentiviral vector as Zynteglo. On 18 February 2021 the CHMP was requested to assess the impact thereof on the benefit-risk balance of Zynteglo and to give its recommendation whether the marketing authorisation of this product should be maintained, varied, suspended or revoked. As the request results from the evaluation of data resulting from pharmacovigilance activities, the CHMP opinion was adopted on the basis of a recommendation of the Pharmacovigilance Risk Assessment Committee.	22/07/2021	16/09/2021	SmPC, Annex II and PL	Please refer to the assessment report: Zynteglo EMEA/H/A-20/1504/C/003691/0023

R/0018	Renewal of the marketing authorisation.	22/07/2021	16/09/2021		The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Zynteglo, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.
IB/0026/G	This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	11/09/2021	n/a		
PSUSA/10769 /202011	Periodic Safety Update EU Single assessment - betibeglogene autotemcel	08/07/2021	n/a		PRAC Recommendation - maintenance

II/0022	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	20/05/2021	n/a		
IB/0024	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	03/05/2021	n/a		
PSUSA/10769 /202005	Periodic Safety Update EU Single assessment - betibeglogene autotemcel	14/01/2021	n/a		PRAC Recommendation - maintenance
N/0020	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	18/12/2020	09/07/2021	PL	
II/0017	B.I.e.2 - Introduction of a post approval change management protocol related to the AS	10/12/2020	n/a		
IAIN/0019/G	This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder	01/12/2020	09/07/2021	Annex II and PL	

	or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
IB/0016	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	04/11/2020	n/a		
IA/0015/G	This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	28/08/2020	n/a		

	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information				
PSUSA/10769 /201911	Periodic Safety Update EU Single assessment - betibeglogene autotemcel	09/07/2020	n/a		PRAC Recommendation - maintenance
IB/0013	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	08/07/2020	09/07/2021	Annex II and Labelling	
IB/0012	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	06/07/2020	n/a		
IB/0011	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	29/05/2020	n/a		
R/0005	Renewal of the marketing authorisation.	27/02/2020	28/04/2020	SmPC, Annex II and PL	The CAT/CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Zynteglo, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.

IA/0008	B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol	21/02/2020	n/a		
IB/0009	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	20/02/2020	n/a		
IB/0007	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	03/02/2020	n/a		
IB/0006	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	20/12/2019	n/a		
IB/0004/G	This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	18/12/2019	n/a		
IB/0003	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	31/10/2019	28/04/2020	SmPC, Annex II, Labelling and PL	

II/0001/G	This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits	17/10/2019	n/a		
IB/0002	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	30/08/2019	n/a		